Waltz M, Juengst ET, Edwards T, Henderson GE, Kuczynski KJ, Conley JM, Della-Penna P, Cadigan RJ. The view from the benches: scientists' perspectives on the uses and governance of human gene-editing research. CRISPR J. 2021 Aug;4(4):609-15. doi: 10.1089/crispr.2021.0038
Karanth SS, Lairson DR, Savas LS, Vernon SW, Fernandez ME. The cost of developing a computerized tailored interactive multimedia intervention vs. a print based photonovella intervention for HPV vaccine education. Eval Program Plann. 2017 Aug;63:1-6. doi: 10.1016/j.evalprogplan.2017.02.009
Mauskopf J, Chirila C, Birt J, Boye KS, Bowman L. Drug reimbursement recommendations by the National Institute for Health and Clinical Excellence: have they impacted the National Health Service budget? Health Policy (New York). 2013 Apr 1;110(1):49-59.
Richter A, Hicks KA, Earnshaw SR, Honeycutt AA. Allocating HIV prevention resources: a tool for state and local decision making. Health Policy (New York). 2008 Sep 1;87(3):342-9.
Lovas K, Kalo Z, McKenna SP, Whalley D, Pentek M, Genti G. Establishing a standard for patient-completed instrument adaptations in Eastern Europe: experience with the Nottingham Health Profile in Hungary. Health Policy (New York). 2003 Jan 1;63(1):20.
McKenna SP, Whalley D. Assessment of biotechnology drugs: what are the issues? Letter to the editor. Health Policy (New York). 1999 Nov;49(3):195-7. doi: 10.1016/S0168-8510(99)00055-X
French MT, Bradley CJ, Calingaert B, Dennis ML, Karuntzos GT. Cost analysis of training and employment services in methadone treatment. Eval Program Plann. 1994 Apr 1;17(2):107-20.